299 related articles for article (PubMed ID: 31512601)
1. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug-Able Anti-TB Phytochemicals: A Cost-Effective Platform for Natural Product-Based Drug Discovery.
Swain SS; Hussain T
Chem Biodivers; 2022 Nov; 19(11):e202200267. PubMed ID: 36307750
[TBL] [Abstract][Full Text] [Related]
5. Computational biology in anti-tuberculosis drug discovery.
Murphy DJ; Brown JR
Infect Disord Drug Targets; 2009 Jun; 9(3):319-26. PubMed ID: 19519485
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
7. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential inhibitors for mycobacterial uridine diphosphogalactofuranose-galactopyranose mutase enzyme: A novel drug target through in silico approach.
Nayak T; Jena L; Waghmare P; Harinath BC
Int J Mycobacteriol; 2018; 7(1):61-68. PubMed ID: 29516888
[TBL] [Abstract][Full Text] [Related]
9. In silico analyses for the discovery of tuberculosis drug targets.
Chung BK; Dick T; Lee DY
J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
[TBL] [Abstract][Full Text] [Related]
10. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.
Ezati N; Lukoye D; Wampande EM; Musisi K; Kasule GW; Cobelens FG; Kateete DP; Joloba ML
BMC Infect Dis; 2014 Dec; 14():703. PubMed ID: 25523472
[TBL] [Abstract][Full Text] [Related]
11. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin.
Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y
J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025
[TBL] [Abstract][Full Text] [Related]
12. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
13. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
[TBL] [Abstract][Full Text] [Related]
14. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
[TBL] [Abstract][Full Text] [Related]
15. Data Intensive Genome Level Analysis for Identifying Novel, Non-Toxic Drug Targets for Multi Drug Resistant Mycobacterium tuberculosis.
Kaur D; Kutum R; Dash D; Brahmachari SK
Sci Rep; 2017 Apr; 7():46595. PubMed ID: 28425478
[TBL] [Abstract][Full Text] [Related]
16. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
[TBL] [Abstract][Full Text] [Related]
17. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
18. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.
Swaminathan S; Sundaramurthi JC; Palaniappan AN; Narayanan S
Tuberculosis (Edinb); 2016 Dec; 101():31-40. PubMed ID: 27865394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
